Trial site
Jerusalem
Jerusalem, 9112001, IsraelNot linked to an institution yet
- 12running trials
- 4closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 1/22 trials
- Phase 22 trials
- Status
- Active, not recruiting6 trials
- Recruiting6 trials
- Completed3 trials
- Withdrawn1 trial
- Lead sponsor
- GlaxoSmithKline15 trials
- Tesaro, Inc.1 trial
Running trials
Recruiting
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
NCT07602777· Phase 1/2· GlaxoSmithKline· Source
Contact: Adi Nitzan-Luques (principal investigator)
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051· Phase 2· GlaxoSmithKline· Source
Contact: Gabriel Izbicki (principal investigator)
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898· Phase 3· GlaxoSmithKline· Source
Contact: Yakir Rottenberg (principal investigator)
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214· Phase 3· GlaxoSmithKline· Source
Contact: Neville Berkman (principal investigator)
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101· Phase 3· GlaxoSmithKline· Source
Contact: Revital Saban (principal investigator)
Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
NCT05714839· Phase 1/2· GlaxoSmithKline· Source
Contact: moshe gatt (principal investigator)
Active, not recruiting
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Linerixibat Long-term Safety, and Tolerability Study
NCT04167358· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
NCT03981796· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113· Phase 2· GlaxoSmithKline· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error